阿卡波糖與達格列凈治療2型糖尿病的臨床效果及藥物不良反應(yīng)分析

打開文本圖片集

中圖分類號：R587.1文獻標識碼：A

DOI：10.3969/j.issn.1006-1959.2025.12.029 文章編號：1006-1959（2025）12-0136-04

Analysis of Clinical Effect and Adverse DrugReactionsof Acarboseand Dapagliflozin intheTreatmentof Type2DiabetesMellitus

ZHU Jian

（DepartmentofPharmacy，Yanshan CountyHospitalofTraditionalChinese Medicine，Yanshan3345o，Jiangxi，China）

Abstract：ObjectieToalyethenicalefectnddversedgreactiosofcarboenddapaglfoinintetreatmentoftyabee mlitus（D.etosigdoerableto63sitdtdtsotitalofdioal ChineseMediefroJauarytoDceber3eredivideditoarboseoup31patints）nddapaglflingrou32patints）hc wertreatediabdalsiellccodosptelodcole bldcoee） fluctuationdeelefccusiGE）filfes）htsted reactionswerecomparedbetweethetogroupsesultsereasnsiificantdiereceinbloodglucosecomplancerateandldglucoe compliance time between the two groups（ P>0 0.05）.The indexesofFPG，2hPBGand HbAlcinthetwo groups werelower than those before treatment （ P< 0.05），butthere wasnosignificant diffrence inFPG，2hPBGandHbAlc between the two groupsafter treatment（ P> 0.05）. The values of MAGE and MODD in the dapagliflozin group were lower than those in the acarbose group（ P <0.05）.The bodyweight and waist circumference of the two groupsaftertreaeerelesstantoefotreantndodytandistfereeoftapalifoplesta those of the acarbose group（ P<0.05 ）.The incidence of adverse drug reactions in dapagliflozin group（ 3.13% ）was lower than that in acarbose group （19.35 % ）（ P?

Keywords：Typedabetesmelitus;Acarbose;Dapaglifloin;HypoglycemicfcacyAdversereactions;Weight;Wistiuence

2型糖尿?。╰ype2diabetesmellitus，T2DM）為我國高發(fā)內(nèi)分泌疾病，以糖代謝紊亂為典型特征，其病情可累及多個器官組織，引發(fā)心、腦、腎等血管系統(tǒng)并發(fā)癥，嚴重威脅患者身心健康及生存質(zhì)量[2]。（剩余5030字）